Abstract
Reduced-intensity conditioning (RIC) allo-SCT is a potentially curative treatment approach for patients with relapsed Hodgkin's or non-Hodgkin's lymphoma. In the present study, 37 patients underwent RIC allo-SCT after induction treatment with EPOCH-F(R) using a novel form of dual-agent immunosuppression for GVHD prophylaxis with CsA and sirolimus. With a median follow-up of 28 months among survivors, the probability for OS at 3 and 5 years was 56%. Treatment-related mortality was 16% at day +100 and 30% after 1 year of transplant. Acute GVHD grades II-IV developed in 38% of patients, suggesting that the regimen consisting of CsA and an ultra-short course of sirolimus is effective in the prevention of acute GVHD.
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Graft vs Host Disease / etiology
-
Graft vs Host Disease / prevention & control*
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Hematopoietic Stem Cell Transplantation / methods*
-
Hodgkin Disease / drug therapy
-
Hodgkin Disease / surgery
-
Hodgkin Disease / therapy*
-
Humans
-
Immunosuppressive Agents / administration & dosage*
-
Lymphoma, Non-Hodgkin / drug therapy
-
Lymphoma, Non-Hodgkin / surgery
-
Lymphoma, Non-Hodgkin / therapy*
-
Male
-
Middle Aged
-
Prednisolone / administration & dosage
-
Rituximab
-
Sirolimus / administration & dosage*
-
Transplantation Conditioning / methods*
-
Transplantation, Homologous
-
Vidarabine / administration & dosage
-
Vidarabine / analogs & derivatives
-
Vincristine / administration & dosage
-
Young Adult
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Immunosuppressive Agents
-
Rituximab
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Prednisolone
-
Vidarabine
-
fludarabine
-
Sirolimus